SOPHiA Genetics articles

Clinical trials are the backbone of modern medicine, responsible for bringing innovative, safe, and efficient treatments to market after rigorous testing and evaluation. However, the conventional process of conducting these trials has often been long, expensive, and fraught with inefficiencies¹. The advent of predictive analytics is reshaping the landscape of clinical trials, ushering in a new era of precision efficiency². This blog explores how predictive analytics is tran

Discover how matched tumor-normal sequencing can help clinical researchers detect the somatic origin of variants with certainty.

In the era of precision oncology, it has become increasingly common for patients diagnosed with cancer to undergo tumor sequencing. Identifying the mutations that make up a tumor’s genomic landscape can help guide selection of targeted therapies and inform prognosis. Despite the recognized value of tumor-only sequencing, labs performi

Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹?³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and achieve global health equity.

In response to the emerging needs in global healthcare, SOPHiA GENETICS has just revealed the New Generation SOPHiA DDM™ Platform, aiming to stay at the forefront of precision medicine and address today the healthcare needs of tomorrow.

ESMO updated its recommendations for NGS in advanced cancers this year, urging broader use of NGS in additional cancer types and the inclusion of tumor-agnostic biomarkers.

The ESMO Precision Medicine Working Group (PMWG) first published its recommendations for when to use next-generation sequencing (NGS) in routine practice for patients with metastatic cancers in 2020¹. At that time, based on identification of recurrent genomic alterations in the eight mo